Locations:
Search IconSearch
March 27, 2019/Neurosciences/Research

A Window into Patients’ Perceptions of the Risks of Multiple Sclerosis Therapies

Large survey shows wide variability in risk tolerance, high levels of risk aversion

19-NEU-258-Woman-MS-Wheelchair-640241694

Individuals with multiple sclerosis (MS) show wide variability in their levels of risk tolerance to MS therapies, concludes the most comprehensive study of the issue reported to date.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The Cleveland Clinic-led study, recently published in Neurology (2019 Mar 19 [Epub ahead of print]), carries implications for how MS clinicians may better guide patients toward individualized treatment choices, says lead author Robert Fox, MD, a neurologist with Cleveland Clinic’s Mellen Center for Multiple Sclerosis Treatment and Research. “Understanding variations in risk perception and tolerance can ultimately lead to greater patient satisfaction with therapy choices — and perhaps better treatment adherence,” he explains.

A survey on real-world risks of a hypothetical MS med

Dr. Fox and colleagues invited people with MS from the North American Research Committee on Multiple Sclerosis Registry (NARCOMS) and the National Multiple Sclerosis Society website to complete an online survey on their tolerance to real-world risks associated with a hypothetical disease-modifying therapy (DMT) for MS.

After being told the DMT would yield a fixed benefit — i.e., a 50 percent reduction in relapses and 30 percent slowing of disability — survey participants were asked if they would take the therapy if it were associated with a specific risk that occurs at a rate of 1 in 1,000 people. If they responded yes, they were asked if they would take it if the risk level were higher — say, 1 in 100 people. If they responded no, they were asked if they’d take the medication if the risk were lower — say, 1 in 10,000 people. Multiple risk levels were presented to pinpoint respondents’ maximum tolerance for each of six adverse effects associated with actual commercially available DMTs:

  • Skin rash
  • Infection
  • Kidney injury
  • Thyroid injury
  • Liver injury
  • Progressive multifocal leukoencephalopathy (PML)

Advertisement

Key results from over 3,000 respondents

The survey was completed by 3,171 people with MS (mean age, 55.1 years) over a one-month period in 2016. Key findings included the following:

  • Risk tolerance was lowest for PML and kidney injury (1:1,000,000 for each) and highest for thyroid injury and infection (1:1,000 for each).
  • Men, younger patients (< 41 years) and those with greater levels of disability (Patient Determined Disease Steps score ≥ 6) had the highest risk tolerance under all scenarios.
  • About 53 percent of participants reported current use of a DMT, and these individuals showed greater risk tolerance in all scenarios. Across the board, those taking oral and infusion DMTs were more risk-tolerant than those taking injectables.
  • Despite variable risk tolerance throughout the sample, a large share of participants were risk-averse: 17 to 39 percent were unwilling to assume any risk for a beneficial therapy, depending on the specific adverse effect.
  • In contrast, fewer than 2 percent of respondents were willing to accept any risk for the benefit of the hypothetical DMT.

A need for more conversation around acceptable risk

Dr. Fox acknowledges that the survey was limited by a single fixed benefit (50-percent relapse reduction plus 30-percent disability slowing) and its focus on just six potential — albeit commonly reported — risks of DMTs.

“Nevertheless,” he observes, “identifying the best therapy for a patient involves not only assessing a medication’s benefits and risks but also an awareness of the patient’s perception of acceptable risk. These findings outline some general trends around those perceptions and underscore the importance of initiating conversations about acceptable risks, given the large heterogeneity we found in patient perceptions and comfort levels.”

Advertisement

An accompanying editorial in Neurology echoes that view: “Fox et al. provide cause for serious reflection on the issue of MS patient perception of, and response to, the risks involved in DMTs,” write editorialists Gavin V. McDonnell, MD, from Northern Ireland, and James J. Marriott, MD, from Canada. Noting concern “that so many patients are apparently averse to any level of risk for what many would perceive to be a reasonable level of benefit,” the editorialists conclude that “it is incumbent on us to develop strategies for communicating both treatment risks and benefits effectively and succinctly.”

Advertisement

Related Articles

MRI of the brain against black background
Advanced Neuroimaging and Clinical Perseverance Make Sense of a 68-Year-Old’s Progressive Symptoms

A case study in pairing imaging acumen with subspecialty expertise to yield answers and symptom relief

brain scan with colored dots over a dark gray region
March 3, 2026/Neurosciences/Epilepsy
Decoding the Insula: New Semiological Insights for Localizing Seizure Onset

Guidance from the largest cohort of SEEG-confirmed insular epilepsy patients reported to date

Photo of Dr. Ford
March 2, 2026/Neurosciences/Podcast
Neuroethics Conversations: Guidelines for Care (Podcast)

Ethical guidance provides guardrails so medical advances benefit patients

red blood cells floating in a blood vessel
February 27, 2026/Neurosciences/Cerebrovascular
Factor XIa Inhibition Drives Down Recurrent Stroke Risk Without Rise in Bleeding

OCEANIC-STROKE results represent long-sought advance in secondary stroke prevention

two brightly colored brain scans side by side
February 25, 2026/Neurosciences/Epilepsy
MR Fingerprinting Shows Potential to Reshape FCD Detection and Epileptogenicity Mapping

Two studies from Cleveland Clinic may help advance the technology toward broader clinical use

MRI scan of the side of a human head
February 20, 2026/Neurosciences/Cerebrovascular
Susac Syndrome: Insights on Rare Endotheliopathy From Largest Single-Center Cohort to Date

Distinct MRI signature includes lesions beyond the corpus callosum, features predictive of vision and hearing loss

Symbolic photo illustration: stethoscope on a medical dictionary
Is ‘Atypical Parkinsonism’ a Useful Term?

An argument for clarifying the nomenclature

Dr. Jagan Pillai against a decorative background
February 16, 2026/Neurosciences/Podcast
Blood Tests For Alzheimer’s: Diagnostic Help Comes With New Questions Too (Podcast)

An expert talks through the benefits, limits and unresolved questions of an evolving technology

Ad